Key Takeaways
- Broad-based pricing recovery drove the quarter: Realizations improved meaningfully across chlorotoluene, phosphoric acid, hydrogen peroxide and caustic soda, lifting both domestic (+29% YoY) and export (+14% YoY) sales.
- Renewable energy push is cutting power costs, but the glide path has friction: RE share hit ~55% in Q2, pulling the H1 average rate to ₹7.09/unit from ₹7.6/unit, yet DISCOM rate hikes and a delay in the ABRen long-term project partially offset the benefit.
- Chlorine integration is the margin unlock story, now with a quantified target: Management aims to lift chlorine integration to 75% in 2–3 years as the HCl synthesis and phosphoric acid pipeline commissions, a shift that would structurally reduce the drag from volatile chlorine realizations.
- The ₹10,000 crore ambition is a 2031 aspiration, not a plan with a price tag: Management declined to put a capex figure on the target, noting products are still being identified under the Kearney-led growth strategy, making the goal contingent on market conditions, execution, and the chemical cycle.
- What to watch next quarter: Whether the post-September caustic soda realization improvement holds against rising energy costs, the pace of chlorotoluene downstream project execution, and any concrete disclosure on the battery-storage RE investigation.
Pricing & Realizations
- Value-added products led the uplift: Chlorotoluene and its derivatives commanded pricing roughly double the prior year same quarter, phosphoric acid improved ~44%, hydrogen peroxide ~31%, and the caustic soda group added ~10%.
- Chlorine swung from a liability to a contributor: Chlorine prices, which had been substantially negative, improved significantly during the quarter, helping sustain ECU levels even as other input costs moved. Management described the direction but did not quantify current levels when asked.
- Post-quarter caustic soda exit rates are better, but energy costs linger: Current realizations are relatively better than Q2, though management declined to give a precise number, and noted that energy cost impacts remain a counterweight.
Management: "Current market realizations are better than Q2, especially if you are talking about the caustic soda. However, the energy cost impacts are there. Precisely, a number to be given may not be appropriate at this time."
Energy & Power Cost
- Renewable share jumped, but the cost benefit was muted by two headwinds: RE accounted for ~55% of power consumption in Q2 (vs 38% YoY), yet the average H1 power rate fell only to ₹7.09/unit from ₹7.6/unit because DISCOM rates rose ~₹0.45/unit and the long-term ABRen project was delayed, forcing reliance on short-term RE.
- The H1 actual mix shows the transition is still underway: 43% dependence on DISCOM plus GNAL captive (81 MW), 28% short-term RE (52 MW), and 29% own wind farms (53 MW).
- The RE roadmap has specific cost targets: 60% RE share by March 2027, aiming to reduce power cost to ₹6.18/kWH; 80% by FY30, targeting less than ₹6/kWH. Battery-storage RE is under investigation, with details promised once approvals reach a certain level.
Chlorine Integration & Capacity Expansion
- The integration target is now explicit: Management aims to reach almost 75% chlorine integration in 2–3 years, up from current levels, once the full capex pipeline of chlorine-consuming plants is commissioned.
- Near-term commissioning milestones: A 200 TPD caustic soda flaking facility at Dahej is targeted for December this year; a 120 TPD HCl synthesis unit around January 2027; chlorotoluene downstream Phase 1 units by March 2027.
- Longer-duration projects are stacking up: Food-grade phosphoric acid expansion, caustic soda revamping, KOH expansion, an electronic-grade hydrogen peroxide plant (January 2028), and an additional HCl synthesis unit (next year or two) are all under implementation.
- Chlorotoluene utilization ramped sharply: Production increased substantially as utilization reached approximately 90%, supporting both domestic pricing and export expansion into the U.S., U.K., and Europe.
Management: "This percentage is likely to go up to almost 75% once our entire capex pipeline, which involves the chlorine integration plants, would be commissioned. Our aim is to reach the 75% in the next two to three years."
Export & Market Diversification
- Export footprint widened across products and geographies: Phosphoric acid, caustic soda prills, and methylene dichloride all saw expanded export reach; chlorotoluene sales strengthened in the U.S., U.K., and Europe; Benzaldehyde exports to the United States commenced.
- Europe is the strategic caustic soda target: Management sees a promising export opportunity as India positions as the world's third-largest producer, with Europe a key market for both liquid and solid forms.
- The response to large competing capacities is cost and market penetration: Management's stated strategy is to focus on cost, efficiency, and market penetration, seeing brighter opportunities in global markets that will balance supply over time.
Management: "The large capacities which are coming, while as GACL, we are focusing on our cost and market penetrations and improve efficiencies. That would be the sole way to handle it. We see a brighter opportunities in the global markets, and that's how that market is going to get balanced in due course of time."
GNAL JV & Operational Updates
- GNAL delivered a broad-based improvement: Higher production and sales, improved realization, and lower financing costs drove Q2 sales growth of ~23% and EBITDA growth of ~19%. With the plant now stabilized at optimum capacity and higher caustic soda and hydrogen sales, management hopes to sustain performance over the year.
- Hydrazine hydrate ramp-up will be a slow burn: Management cautioned that ramp-up will take time and prefers to evaluate the business over a longer operating horizon rather than on the basis of one or two quarters.
- Some plants faced operational headwinds: Plant shutdowns, grid disturbances, feedstock constraints, and operational issues meant overall capacity utilization was marginally lower versus the prior year, though plants producing higher-realization products broadly did well.
Project Ahvaan & the 2031 Aspiration
- The strategic transformation exercise is underway: Project Ahvaan focuses on efficiency, energy, procurement, production, and plant operations, with power as the primary focus. The stated strategic objective is to reach revenue of ₹10,000+ crores by 2031 with EBITDA over 20%.
- The aspiration is explicitly not near-term guidance: Management stressed that achievement depends on market conditions, project execution, energy and raw material prices, and the chemical cycle.
- The growth strategy is still being defined: Kearney is preparing the strategy, products for diversification are being identified, and Board approvals plus capex details will be shared at an appropriate point. Management declined to give a specific capex figure required to reach the ₹10,000 crore target, noting products are still being identified.
- Funding will mix internal accruals and borrowings: Initiatives already taken are expected to contribute to increased cash generation over the next 1–2 years, though closing debt and capex numbers for FY27 are difficult to give at this point.
Avantika Singh: "We have articulated an aspiration of becoming a INR10,000 crores plus revenue company with EBITDA margins above 20% by FY 2031. This remains a medium-term aspiration rather than near-term financial guidance, and its achievement will naturally depend on market conditions, project execution, energy and raw material prices, and the chemical cycle."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| RE power share | Reach 60%, reducing power cost to ₹6.18/kWH | By March 2027 |
| RE power share | Reach 80%, reducing power cost to less than ₹6/kWH | By FY30 |
| Chlorine integration | Reach 75% once full chlorine integration capex pipeline commissioned | Next 2–3 years |
| 200 TPD caustic flaking unit | Commission at Dahej | December 2026 |
| 120 TPD HCl synthesis unit | Commission | Around January 2027 |
| Chlorotoluene downstream Phase 1 | Commission | By March 2027 |
| Electronic-grade hydrogen peroxide plant | Commission | Around January 2028 |
| Additional HCl synthesis unit | Commission (board in-principle approval received) | Next year |
| FY29 planned projects | Boilers, KOH expansion at Vadodara, food-grade phosphoric acid second plant at Dahej | FY29 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations (standalone) | ₹1,358 cr, vs ₹1,083 cr in Q2 FY26 |
| External sales revenue | ₹1,334.79 cr, highest quarterly sales in last two decades |
| EBITDA | ₹222 cr, vs ₹133 cr in Q2 FY26 |
| EBITDA margin on total income | 15.74%, vs 11.6% in Q2 FY26 |
| PBT | ₹102 cr, vs ₹13 cr in Q2 FY26 |
| PAT | ~₹79 cr, vs ~₹16 cr in Q2 FY26 |
| H1 FY27 revenue from operations | ₹2,602 cr, vs ₹2,188 cr in H1 FY26 |
| H1 FY27 EBITDA | ₹451 cr, vs ₹258 cr in H1 FY26 |
| H1 FY27 EBITDA margin | 16.95%, vs 11.45% in H1 FY26 |
| H1 FY27 annualized ROCE | ~8.52%, vs 1.87% for FY26 |
| Domestic sales growth | 29% YoY |
| Exports growth | 14% YoY |
| Overall capacity utilization | ~92% |
| Chlorotoluene plant utilization | ~90%, ramped up from prior year |
| Renewable energy share of power consumption | ~55%, vs 38% in Q2 FY26 |
| Average power rate (H1 FY27) | ₹7.09 per unit, vs ₹7.6 in H1 FY26 |
| Current power average cost | ~₹6.95 per kWH, with RE share at 49% |
| Chlorine integration | ~45%, target ~75% in 2–3 years |
| Value-added products share of sales | ~61% of Q2 sales |
| Chlorotoluene group pricing uplift | ~100% vs same quarter previous year |
| Phosphoric acid pricing improvement | ~44% over previous quarter |
| Hydrogen peroxide pricing improvement | 31% over previous quarter |
| Caustic soda group pricing improvement | ~10% |
| GNAL Q2 sales growth | ~23% |
| GNAL Q2 EBITDA growth | ~19% |
| GNAL H1 PBT | ₹8 cr profit, vs loss of ₹36 cr in H1 FY26 |
| Caustic soda liquid exports | ~5 KT per month, ~60,000 tons annual |
| Caustic soda solid exports | ~10,000–12,000 tons per month |
| Closing capital work in progress | ₹434 cr |
| PPE purchases (H1 cash flow) | ₹118 cr |
| Investment in RE SPV (Clean Max) | ₹32.33 cr, equity contribution for 62.7 MW project |